Side effects incldue coughing noisy, rattling, troubled breathing, loss of appetite, aches and pain in joints, indigestion,and skin itching or rash.
Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Artemether | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether. |
| Mifepristone | The serum concentration of Halofantrine can be increased when it is combined with Mifepristone. |
| Quinine | The risk or severity of QTc prolongation, ventricular arrhythmias, torsade de pointes, and convulsion can be increased when Quinine is combined with Halofantrine. |
| Quinidine | The risk or severity of QTc prolongation, ventricular arrhythmias, torsade de pointes, and convulsion can be increased when Quinidine is combined with Halofantrine. |
| Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Halofantrine. |
| Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Halofantrine. |
| Vortioxetine | The metabolism of Vortioxetine can be decreased when combined with Halofantrine. |
| Eliglustat | The metabolism of Eliglustat can be decreased when combined with Halofantrine. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Iloperidone. |
| Tetrabenazine | The metabolism of Tetrabenazine can be decreased when combined with Halofantrine. |
| Sucralfate | Sucralfate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentoquatam | Bentoquatam can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium sulfate | Magnesium sulfate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium salicylate | Magnesium salicylate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Kaolin | Kaolin can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc | Zinc can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc trihydroxide | Zinc trihydroxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc Substituted Heme C | Zinc Substituted Heme C can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lanthanum carbonate | Lanthanum carbonate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Potassium alum | Potassium alum can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Polaprezinc | Polaprezinc can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc oxide | Zinc oxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate | Zinc sulfate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium chloride | Magnesium chloride can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum chloride | Aluminum chloride can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium citrate | Magnesium citrate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc citrate | Zinc citrate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc picolinate | Zinc picolinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum sulfate | Aluminum sulfate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc gluconate | Zinc gluconate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentonite | Bentonite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium acetoacetate | Aluminium acetoacetate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium aspartate | Magnesium aspartate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium peroxide | Magnesium peroxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium glycinate | Aluminium glycinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aloglutamol | Aloglutamol can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Montmorillonite | Montmorillonite can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium gluconate | Magnesium gluconate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium orotate | Magnesium orotate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetylcysteine zinc | Acetylcysteine zinc can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc ascorbate | Zinc ascorbate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc acetate | Zinc acetate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc glycinate | Zinc glycinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium | Magnesium can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium levulinate | Magnesium levulinate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium lactate | Magnesium lactate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc chloride | Zinc chloride can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate, unspecified form | Zinc sulfate, unspecified form can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lanthanum III cation | Lanthanum III cation can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc cation | Zinc cation can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum chlorohydrate | Aluminum chlorohydrate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dihydroxyaluminum sodium carbonate | Dihydroxyaluminum sodium carbonate can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lumefantrine | Lumefantrine may increase the QTc-prolonging activities of Halofantrine. |
| Thiethylperazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Thiethylperazine. |
| Promazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Promazine. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Prochlorperazine. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Chlorpromazine. |
| Triflupromazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Triflupromazine. |
| Fluphenazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Fluphenazine. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Thioridazine. |
| Moricizine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Moricizine. |
| Trifluoperazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Trifluoperazine. |
| Perphenazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Perphenazine. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Mesoridazine. |
| Acetophenazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Acetophenazine. |
| Promethazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Promethazine. |
| Alimemazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Alimemazine. |
| Methotrimeprazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Methotrimeprazine. |
| Periciazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Periciazine. |
| Acepromazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Acepromazine. |
| Aceprometazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Aceprometazine. |
| Pipotiazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Pipotiazine. |
| Thioproperazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Thioproperazine. |
| BL-1020 | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with BL-1020. |
| Cyamemazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Cyamemazine. |
| Methylene blue | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Methylene blue. |
| Propiopromazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Propiopromazine. |
| Perazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Perazine. |
| Butaperazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Butaperazine. |
| Chlorproethazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Chlorproethazine. |
| Thiazinam | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Thiazinam. |
| Dixyrazine | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Dixyrazine. |
| Perphenazine enanthate | The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Perphenazine enanthate. |
| Dapsone | The risk or severity of adverse effects can be increased when Halofantrine is combined with Dapsone. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Halofantrine. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Halofantrine. |
| Erythromycin | The serum concentration of Halofantrine can be increased when it is combined with Erythromycin. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Halofantrine. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Halofantrine. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Halofantrine. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Halofantrine. |